Rock Springs Capital Management LP Has $20.14 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Rock Springs Capital Management LP cut its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 26.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,677,996 shares of the biotechnology company's stock after selling 944,362 shares during the period. Rock Springs Capital Management LP owned approximately 1.29% of BioCryst Pharmaceuticals worth $20,139,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $46,000. R Squared Ltd acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $48,000. KBC Group NV increased its position in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 4,537 shares during the period. Raymond James Financial Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $80,000. Finally, SkyView Investment Advisors LLC lifted its position in BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 3,000 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

BCRX traded up $0.17 during mid-day trading on Friday, reaching $8.39. The stock had a trading volume of 3,208,207 shares, compared to its average volume of 2,803,998. The stock has a market capitalization of $1.75 billion, a P/E ratio of -13.75 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.11 and a 52 week high of $9.50. The firm's fifty day simple moving average is $7.72 and its two-hundred day simple moving average is $7.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter in the previous year, the firm posted $0.28 EPS. The company's revenue for the quarter was up 40.8% on a year-over-year basis. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BCRX shares. Evercore ISI lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. Royal Bank of Canada reissued an "outperform" rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Wedbush assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.